Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer

Keyphrases

• Patients with Breast Cancer 100%
• Pharmacokinetics 100%
• Cytochrome P450 Enzymes 100%
• Randomized Crossover Trial 100%
• Palbociclib 100%
• Erythromycin 100%
• Coefficient of Variation 35%
• Monotherapy 21%
• Cmax 21%
• Plasma Concentration 14%
• Geometric Mean 14%
• Cmin 14%
• Adverse Events 7%
• Confidence Interval 7%
• Cyclin-dependent Kinase 6 (CDK6) 7%
• Metastatic Breast Cancer 7%
• Once-daily 7%
• Neutropenia 7%
• Dosing Schedule 7%
• Area under the Concentration-time Curve 7%
• Dose Reduction 7%
• Minor Differences 7%
• Steady State 7%
• Pharmacokinetic Drug Interactions 7%
• Ratio of Means 7%
• Mean Area 7%
• Locally Advanced Breast Cancer 7%
• Oral Inhibitors 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Cytochrome P450 100%
• Erythromycin 100%
• Palbociclib 100%
• Pharmacokinetics 100%
• Monotherapy 21%
• Cmin 14%
• Pharmacodynamics 7%
• Neutropenia 7%
• Adverse Event 7%
• Metastatic Breast Cancer 7%
• Cyclin Dependent Kinase 4 7%
• Cyclin Dependent Kinase 6 7%